Overview

* Aptose reports Q3 net loss of $5.1 mln, down from $7.0 mln last year

* Research and development expenses decreased due to reduced clinical and manufacturing activity

Outlook

* Company did not provide specific financial guidance

Result Drivers

* R&D: Research and development expenses decreased by $2.5 million to $2.2 million for the quarter ended September 30

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Net -$5.12

Income mln

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)